AstraZeneca: AI collaboration with Absci
Under the terms of the project, millions of protein-protein interactions will be studied to feed Absci's proprietary AI models, with the aim of discovering a drug candidate in the field of oncology.
Financially, the agreement includes an upfront payment, R&D funding and milestone payments, as well as royalties on future product sales.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction